Amplitude-based optimal respiratory gating in positron emission tomography in patients with primary lung cancer
暂无分享,去创建一个
Martin Gotthardt | Wim J. G. Oyen | Eric P. Visser | Willem Grootjans | W. Oyen | E. Visser | M. Gotthardt | W. Grootjans | Lioe-Fee Geus-Oei | Antoi P. W. Meeuwis | Charlotte S. Vos | L. Geus-Oei | A. Meeuwis | C. S. Vos
[1] Vincent Gregoire,et al. Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. , 2011, Seminars in radiation oncology.
[2] Wolfgang A Weber,et al. Use of PET for monitoring cancer therapy and for predicting outcome. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] A comparison of amplitude-based and phase-based positron emission tomography gating algorithms for segmentation of internal target volumes of tumors subject to respiratory motion. , 2013, International journal of radiation oncology, biology, physics.
[4] Danny Rischin,et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Joel Karp,et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] Ursula Nestle,et al. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[7] E Yorke,et al. Four-dimensional (4D) PET/CT imaging of the thorax. , 2004, Medical physics.
[8] W. Oyen,et al. Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer , 2007, Journal of Nuclear Medicine.
[9] R. Coleman,et al. Recommendations on the Use of 18F-FDG PET in Oncology , 2008, Journal of Nuclear Medicine.
[10] W. Oyen,et al. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] M. O'Doherty,et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] Nan-Tsing Chiu,et al. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. , 2012, Radiology.
[13] Michael Bader,et al. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] V. Bettinardi,et al. Motion management in positron emission tomography/computed tomography for radiation treatment planning. , 2012, Seminars in nuclear medicine.
[15] D. Townsend,et al. Method for transforming CT images for attenuation correction in PET/CT imaging. , 2006, Medical physics.
[16] S M Larson,et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding , 1997, Cancer.
[17] E. Sweet,et al. An introduction to the use of diagnostic ultrasound. , 1975, Seminars in nuclear medicine.
[18] S. Nehmeh,et al. Respiratory motion in positron emission tomography/computed tomography: a review. , 2008, Seminars in nuclear medicine.
[19] John W. Clark,et al. Implementation of an Automated Respiratory Amplitude Gating Technique for PET/CT: Clinical Evaluation , 2010, Journal of Nuclear Medicine.
[20] L. Dunn,et al. Motion effects on SUV and lesion volume in 3D and 4D PET scanning , 2011, Australasian Physical & Engineering Sciences in Medicine.
[21] S. Korreman. Motion in radiotherapy: photon therapy , 2012, Physics in medicine and biology.
[22] James Hamill,et al. Optimal gating compared to 3D and 4D PET reconstruction for characterization of lung tumours , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[23] A. Elster,et al. Recommendations on the Use of 18F-FDG PET in Oncology , 2009 .
[24] M. Schwaiger,et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Satoshi Hattori,et al. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy. , 2012, European journal of radiology.
[26] O. Schober,et al. Respiratory gating in positron emission tomography: a quantitative comparison of different gating schemes. , 2007, Medical physics.
[27] Cyrill Burger,et al. PET-CT image co-registration in the thorax: influence of respiration , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[28] Otto S Hoekstra,et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] P. Ell,et al. Clinical role of positron emission tomography in oncology. , 2001, The Lancet. Oncology.